세계의 Rozanolixizumab(Rystiggo) 시장 규모, 점유율, 동향 분석 : 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Rozanolixizumab (Rystiggo) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Emerging Pipeline Applications), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,251,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,638,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,411,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

Rozanolixizumab(Rystiggo) 시장 요약

세계의 Rozanolixizumab(Rystiggo) 시장 규모는 2024년에 2억 1,861만 달러로 추정되며, 2025-2033년에 15.22%의 CAGR로 성장하며, 2033년에는 17억 40만 달러에 달할 것으로 예측됩니다. 만성 심상성 건선과 관절염성 건선의 유병률 증가로 인해 첨단 생물제제에 대한 수요가 확대되고 있습니다.

중증근무력증(gMG)에 대한 승인이 시장을 주도할 것입니다. 국제적인 추세는 표적치료제에 대한 수요 증가, 승인 가능성 및 의료 접근성 증가에 힘입어 전 세계 규제 당국의 승인이 증가하고 있으며, UCB의 혁신적인 접근 방식과 새로운 파이프라인이 성장을 지원하고 있습니다. 로자놀릭시주맙(Rystiggo) 시장은 만성 자가면역질환인 gMG를 표적으로 하고 있으며, 유병률 증가가 수요를 견인하고 있습니다. 미국과 유럽에서 승인된 Rystiggo는 피하투여가 가능하고 IgG 항체를 감소시키는 효과가 있으며, 채택에 박차를 가하고 있습니다. UCB는 적응증 확대에 주력하고 있으며, 2033년까지 적응증 확대에 집중하고 있으며, 시장 성장은 자가면역질환의 진단율 증가와 고령화 추세에 따라 더욱 가속화될 것으로 예측됩니다.

Rystiggo의 주요 장점은 새로운 FcRn 표적 메커니즘에 있으며, MycarinG 시험에서 입증된 바와 같이 삼킴 및 호흡과 같은 gMG 증상을 크게 개선하는 데 있습니다. 혈장교환과 비교하여 효능을 유지하면서 부작용을 줄일 수 있습니다. 피하투여는 환자의 편의성을 높여 정맥주사 경쟁 약물에 비해 유리한 위치를 점하고 있습니다.

새로운 혁신으로는 만성 염증성 탈수초 증후군(CIDP)에 대한 시험과 자가 투여법 등이 있습니다. 파이프라인이 성공적으로 확장되면 2033년까지 대응 가능한 시장이 두 배로 늘어날 수 있습니다. 전달 시스템의 발전은 컴플라이언스 개선을 목표로 하고 있으며, 바이오시밀러의 가능성은 장기적으로 비용과 접근성의 균형을 맞추면서 경쟁을 가져올 수 있습니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 Rozanolixizumab(Rystiggo) 시장 : 변동 요인·동향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 Rozanolixizumab(Rystiggo) 시장 : 적응증별 비즈니스 분석

• 시장 점유율 : 적응증별(2024년·2033년)
• 부문 대시보드 : 적응증별
• 시장 규모 예측과 동향 분석 : 적응증별(2021-2033년)
• 전신성 중증근무력증(gMG)
• 기타

제5장 Rozanolixizumab(Rystiggo) 시장 : 유통 채널 비즈니스 분석

• 시장 점유율 : 유통 채널별(2024년·2033년)
• 부문 대시보드 : 유통 채널별
• 시장 규모 예측과 동향 분석 : 유통 채널별(2021-2033년)
• 병원·전문 약국
• 소매·E-Commerce

제6장 Rozanolixizumab(Rystiggo) 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2033년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석 : 지역별(2021-2033년)
• 북미
  • 국가별(2021-2033년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여 기업의 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/상장기업
  • UCB

KSA

영문 목차

영문목차

Rozanolixizumab (Rystiggo) Market Summary

The global rozanolixizumab (Rystiggo) market size was estimated at USD 218.61 million in 2024 and is projected to reach USD 1,700.40 million by 2033, growing at a CAGR of 15.22% from 2025 to 2033. The increasing prevalence of chronic plaque psoriasis and psoriatic arthritis drives greater demand for advanced biologic therapies.

The market is driven by its approval for generalized myasthenia gravis (gMG). Key trends include rising demand for targeted therapies and global regulatory approvals, fueled by potential approvals and increasing healthcare access. Growth is supported by UCB's innovative approach and emerging pipeline applications. The rozanolixizumab (Rystiggo) market targets gMG, a chronic autoimmune disorder, with growing prevalence driving demand. Approved in the U.S. and Europe, Rystiggo's subcutaneous administration and efficacy in reducing IgG antibodies fuel its adoption. Market growth is propelled by rising diagnosis rates and an aging population susceptible to autoimmune diseases. UCB's focus on expanding indications further supports the projected increase by 2033.

Rystiggo's key advantage lies in its novel FcRn-targeting mechanism, offering significant improvements in gMG symptoms like swallowing and breathing, as demonstrated in the MycarinG study. Compared to plasma exchange, it reduces side effects while maintaining efficacy. Its subcutaneous delivery enhances patient convenience, positioning it favorably against intravenous competitors.

Emerging innovations include trials for chronic inflammatory demyelinating syndrome (CIDP) and self-administration methods. Successful pipeline expansion could double the addressable market by 2033. Advances in delivery systems aim to improve compliance, while potential biosimilars may introduce competition, balancing cost and accessibility in the long term.

Global Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rozanolixizumab (Rystiggo) market report based on indication, distribution channel and region:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Generalized Myasthenia Gravis (gMG)
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital & Specialty Pharmacies
• Retail & E Commerce
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Generalized Myasthenia Gravis (gMG)
  • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital & Specialty Pharmacies
  • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
• 5.5. Retail & E-Commerce
  • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Rozanolixizumab (Rystiggo) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Rozanolixizumab (Rystiggo) Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Rozanolixizumab (Rystiggo) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. UCB
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives

관련자료